Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens
Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens is a PHASE1 clinical asset sponsored by Medigene AG in Acute Myeloid Leukemia. SEO and diligence focus: WT1/PRAME vaccination, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Acute Myeloid Leukemia
Modality: protein therapy
Target: WT1/PRAME vaccination
Sponsor: Medigene AG
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: WT1/PRAME vaccination
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: WT1/PRAME vaccination
Target normalized: WT1/PRAME vaccination